The results showed that there was no statistical evidence of association between NADPH oxidase p22phoxC242T polymorphism and DN in all genetic models (T vs. C: OR 1.16, 95% CI 0.85-1.59, p=0.34; TT vs. CC: OR 1.49, 95% CI 0.80-2.76, p=0.21; TT/CT vs. CC: OR 1.18, 95% CI 0.81-1.72, p=0.40; TT vs.
We investigated associations of variants in the CYBA gene, encoding the regulatory subunit p22(phox) of NADPH oxidase, with diabetic nephropathy and plasma AOPP and myeloperoxidase (MPO) concentrations in type 1 diabetic patients.
No significant difference was observed in the genotype and allele distribution of eNOS -786T > C, intron 4a4b, p22phox 242C > T and XRCC1 Arg399Gln polymorphisms between T2DM groups with and without DN.
Potential candidate genes in these regions that have been implicated in diabetic nephropathy and/or renal damage in models of hypertension include CYBA (or P22PHOX) (16q24), NOX1 (10q22), and NOX3 (6q25.1-q26).
Further studies should be performed to clarify whether it exists, and to what extent there is a relationship between the p22phoxC242T polymorphism and DN.
We studied the relation between the genotypes of the NADPH p22phoxC242T and RAGE G1704T polymorphisms and the development of diabetic nephropathy in type 2 diabetic patients.
We studied the relation between the genotypes of the NADPH p22phox C242T and RAGE G1704T polymorphisms and the development of diabetic nephropathy in type 2 diabetic patients.